The Effect of Oxytocin on Face Perception

NCT02091817 | Suspended Early Phase 1

• 2 other identifiers: sor010712ctilISF, 384/10
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to determine whether oxytocin affect face perception

Conditions

Healthy; Congenital Prosopagnosia

Keywords

oxytocin; face; memory

Outcome Measures

Primary Outcomes (1)

• Memory performance

  At the day participants will administer the substance, they will view a set of faces, of which they will be tested about 24 hours later. The measures that will be tested are %accuracy and %dwell time of eye movements towards each region in the faces the participants saw.

  Day 2 (24 hours after encoding)

Secondary Outcomes (1)

• Mood measurement

  Day 1 (after oxytocin/placebo uptake)

Study Arms (2)

Control group

OTHER

Control group will be administered oxytocin and placebo, in a double-blind randomized order.

Drug: Oxytocin; Drug: Placebo

congenital prosopagnosia

EXPERIMENTAL

Congenital prosopagnosics will be administered oxytocin and placebo in a double-blind randomized order.

Drug: Oxytocin; Drug: Placebo

Interventions

Oxytocin DRUG

Intervention will be examined on control group, and on experimental group as well.

Also known as: syntocinon

Control group; congenital prosopagnosia

Placebo DRUG

Placebo will be given to control group and experimental group as well.

Control group; congenital prosopagnosia

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• normal or corrected to normal vision

You may not qualify if:

• minors
• pregnancy (according to a pregnancy test taken by subjects prior to participation)
• a history of asthma or nasal polyps
• cardiac disorders
• hyponatremia
• acute or chronic renal insufficiency
• liver cirrhosis
• neurological disease
• other chronic disease
• dementia, or lack of judgment

Sponsors & Collaborators

• Soroka University Medical Center: lead
• Ben-Gurion University of the Negev: collaborator

Study Sites (1)

Soroka medical center

Beersheba, Israel, Israel

Location

Related Publications (7)

• Avidan G, Behrmann M. Functional MRI reveals compromised neural integrity of the face processing network in congenital prosopagnosia. Curr Biol. 2009 Jul 14;19(13):1146-50. doi: 10.1016/j.cub.2009.04.060. Epub 2009 May 28.

  PMID: 19481456 BACKGROUND

• Avidan G, Behrmann M. Implicit familiarity processing in congenital prosopagnosia. J Neuropsychol. 2008 Mar;2(1):141-64. doi: 10.1348/174866407x260180.

  PMID: 19334309 BACKGROUND

• Avidan G, Hasson U, Malach R, Behrmann M. Detailed exploration of face-related processing in congenital prosopagnosia: 2. Functional neuroimaging findings. J Cogn Neurosci. 2005 Jul;17(7):1150-67. doi: 10.1162/0898929054475145.

  PMID: 16102242 BACKGROUND

• Behrmann M, Avidan G, Marotta JJ, Kimchi R. Detailed exploration of face-related processing in congenital prosopagnosia: 1. Behavioral findings. J Cogn Neurosci. 2005 Jul;17(7):1130-49. doi: 10.1162/0898929054475154.

  PMID: 16102241 BACKGROUND

• Hasson U, Avidan G, Deouell LY, Bentin S, Malach R. Face-selective activation in a congenital prosopagnosic subject. J Cogn Neurosci. 2003 Apr 1;15(3):419-31. doi: 10.1162/089892903321593135.

  PMID: 12729493 BACKGROUND

• MacDonald E, Dadds MR, Brennan JL, Williams K, Levy F, Cauchi AJ. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology. 2011 Sep;36(8):1114-26. doi: 10.1016/j.psyneuen.2011.02.015. Epub 2011 Mar 23.

  PMID: 21429671 BACKGROUND

• Avidan G, Tanzer M, Hadj-Bouziane F, Liu N, Ungerleider LG, Behrmann M. Selective dissociation between core and extended regions of the face processing network in congenital prosopagnosia. Cereb Cortex. 2014 Jun;24(6):1565-78. doi: 10.1093/cercor/bht007. Epub 2013 Jan 31.

  PMID: 23377287 BACKGROUND

MeSH Terms

Conditions

Prosopagnosia; Facies

Interventions

Oxytocin

Condition Hierarchy (Ancestors)

Agnosia; Perceptual Disorders; Neurobehavioral Manifestations; Neurologic Manifestations; Nervous System Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Disease Attributes; Pathologic Processes

Intervention Hierarchy (Ancestors)

Pituitary Hormones, Posterior; Pituitary Hormones; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Peptides; Amino Acids, Peptides, and Proteins

Study Officials

• Shelef Ilan, MD

  Soroka University Medical Center

  PRINCIPAL INVESTIGATOR

• Galia Avidan, Ph.D

  Ben-Gurion University of the Negev

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Head of medical imaging at Soroka University Medical Center

Study Record Dates

• First Submitted: January 26, 2014
• First Posted: March 19, 2014
• Study Start: November 1, 2013
• Primary Completion: December 1, 2016
• Study Completion: December 1, 2017
• Last Updated: July 2, 2015

Record last verified: 2015-07

Locations

IL (1)